Electrocardiographic Patterns and Arrhythmias in Cardiac Amyloidosis: From Diagnosis to Therapeutic Management-A Narrative Review.

arrhythmias cardiac amyloidosis electrocardiogram

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
20 Sep 2024
Historique:
received: 13 08 2024
revised: 06 09 2024
accepted: 12 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Electrophysiological aspects of cardiac amyloidosis (CA) are still poorly explored compared to other aspects of the disease. However, electrocardiogram (ECG) abnormalities play an important role in CA diagnosis and prognosis and the management of arrhythmias is a crucial part of CA treatment. Low voltages and a pseudonecrosis pattern with poor R-wave progression in precordial leads are especially common findings. These are useful for CA diagnosis and risk stratification, especially when combined with clinical or echocardiographic findings. Both ventricular and supraventricular arrhythmias are common in CA, especially in transthyretin amyloidosis (ATTR), and their prevalence is related to disease progression. Sustained and non-sustained ventricular tachycardias' prognostic role is still debated, and, to date, there is a lack of specific indications for implantable cardiac defibrillator (ICD). On the other hand, atrial fibrillation (AF) is the most common supraventricular arrhythmia with a prevalence of up to 88% of ATTR patients. Anticoagulation should be considered irrespective of CHADsVA score. Furthermore, even if AF seems to not be an independent prognostic factor in CA, its treatment for symptom control is still crucial. Finally, conduction disturbances and bradyarrhythmias are also common, requiring pacemaker implantation in up to 40% of patients.

Identifiants

pubmed: 39337075
pii: jcm13185588
doi: 10.3390/jcm13185588
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Lucio Teresi (L)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.
Heart Institute, Teknon Medical Centre, 08022 Barcelona, Spain.

Giancarlo Trimarchi (G)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.
Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, 56127 Pisa, Italy.

Paolo Liotta (P)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Davide Restelli (D)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Roberto Licordari (R)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Gabriele Carciotto (G)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Costa Francesco (C)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.
Departamento de Medicina UMA, Área del Corazón, Hospital Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), IBIMA Plataforma BIONAND, 29010 Malaga, Spain.

Pasquale Crea (P)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Giuseppe Dattilo (G)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Antonio Micari (A)

Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98100 Messina, Italy.

Michele Emdin (M)

Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, 56127 Pisa, Italy.
Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy.

Antonio Berruezo (A)

Heart Institute, Teknon Medical Centre, 08022 Barcelona, Spain.

Gianluca Di Bella (G)

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.

Classifications MeSH